- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer
October 20th 2025, 7:28pm
Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.
IO102-IO103 Plus Pembrolizumab Improves PFS in Treatment-Naive Advanced Melanoma
October 20th 2025, 6:50pm
IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.
Dr Le on Early Efficacy Data With Sevabertinib Monotherapy in HER2-Mutant NSCLC
October 20th 2025, 4:56pm
Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.
Dr Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC
October 20th 2025, 4:56pm
Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.
Telisotuzumab Adizutecan Demonstrates Activity, Tolerability in Locally Advanced/Metastatic PDAC
October 20th 2025, 3:35pm
Telisotuzumab adizutecan displayed early activity in locally advanced/metastatic PDAC.
Perioperative Pembrolizumab Benefits Persist at 5-Year NSCLC Update
October 20th 2025, 3:17pm
Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.
Sacituzumab Govitecan Plus Pembrolizumab Upholds QOL, Delays Physical Decline in mTNBC
October 20th 2025, 2:50pm
Sacituzumab govitecan plus pembrolizumab may maintain quality of life in patients with previously untreated, PD-L1–positive metastatic TNBC.
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
October 20th 2025, 1:21pm
ESMO Congress: Gynecologic Cancers
Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.
DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer
October 20th 2025, 12:18pm
T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.
ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC
October 19th 2025, 9:40pm
ESMO Congress: Head and Neck Cancer
The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.
Rounding Up Relevant Data in RCC With Drs Beckermann and Rini
October 19th 2025, 9:35pm
OncLive News Network: On Location at ESMO 2025
Brian I. Rini, MD, FASCO, and Katy Beckermann, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in renal cell carcinoma presented during the 2025 ESMO Congress.
Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC
October 19th 2025, 8:56pm
Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.
Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC
October 19th 2025, 8:40pm
The SKYSCRAPER-14 trial did not show a PFS benefit with tiragolumab plus atezolizumab and bevacizumab in untreated HCC, missing its coprimary end point.
212Pb-DOTAMTATE Yields Responses and Shows Disease Control in Pretreated Advanced GEP-NETS
October 19th 2025, 8:15pm
212Pb-DOTAMTATE produced responses with a manageable safety profile in patients with SSTR-positive, PRRT-exposed, unresectable or metastatic GEP-NETs.
Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC
October 19th 2025, 8:14pm
Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.
Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC
October 19th 2025, 8:05pm
Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.
First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer
October 19th 2025, 7:40pm
Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.
Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC
October 19th 2025, 7:32pm
Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.
Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC
October 19th 2025, 7:25pm
Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.
Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease
October 19th 2025, 7:11pm
Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.